NCT07175389View on ClinicalTrials.gov

JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

October 1, 2027

Conditions
Refractory Pancreatic Ductal AdenocarcinomaRefractory Pancreatic Adenocarcinoma
Interventions
DRUG

JDB153

JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.

DRUG

Serplulimab

Serplulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).

Trial Locations (1)

610041

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors
lead

West China Hospital

OTHER

NCT07175389 - JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure | Biotech Hunter | Biotech Hunter